Tsuchiya N, Shiota M, Yamaguchi A, Ito K
Department of Medicine and Physical Therapy, University of Tokyo, Japan.
Arthritis Rheum. 1996 May;39(5):792-6. doi: 10.1002/art.1780390511.
To examine the clinical significance of serum soluble HLA class I antigens (sHLA class I) in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Serum levels of sHLA class I were measured by enzyme-linked immunosorbent assay, using a monoclonal antibody against monomorphic determinant of HLA class I (W6/32) and an enzyme-labeled polyclonal antibody to human beta 2-microglobulin.
The serum sHLA class I concentration was 1.85 +/- 1.15 micrograms/ml (mean +/- SD) in 27 patients with SLE (P < 0.0001 versus normal controls, P = 0.0001 versus RA), 0.61 +/- 0.34 micrograms/ml in 16 patients with RA (P = 0.02 versus normal controls), and 0.41 +/= 0.20 micrograms/ml in normal controls. The HLA class I levels were significantly correlated with the SLE Disease Activity Index (r = 0.62, P = 0.0004) and with a reduction of CH50 levels (r = -0.60, P = 0.0007). A longitudinal analysis of patients with SLE indicated that serum sHLA class I levels fluctuated in conjunction with other disease activity markers.
Serum sHLA class I may be useful as a disease activity marker of SLE. The mechanism of secretion and the physiologic role of sHLA class I require further study.
研究血清可溶性人类白细胞抗原I类抗原（sHLA-I）在系统性红斑狼疮（SLE）和类风湿关节炎（RA）患者中的临床意义。
采用酶联免疫吸附测定法，使用针对HLA-I类单态决定簇的单克隆抗体（W6/32）和酶标记的抗人β2-微球蛋白多克隆抗体，检测血清sHLA-I水平。
27例SLE患者血清sHLA-I浓度为1.85±1.15微克/毫升（均值±标准差）（与正常对照组相比，P<0.0001；与RA相比，P = 0.0001）；16例RA患者血清sHLA-I浓度为0.61±0.34微克/毫升（与正常对照组相比，P = 0.02）；正常对照组血清sHLA-I浓度为0.41±0.20微克/毫升。HLA-I水平与SLE疾病活动指数显著相关（r = 0.62，P = 0.0004），与CH50水平降低显著相关（r = -0.60，P = 0.0007）。对SLE患者的纵向分析表明，血清sHLA-I水平与其他疾病活动指标同步波动。
血清sHLA-I可能作为SLE的疾病活动标志物。sHLA-I的分泌机制和生理作用有待进一步研究。
